

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

IVAN HOFMANN
UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE) Case: IPR2015-00990 and
DRUGS II, LLC,) IPR2015-01093
Petitioner,)
- against -) Patent: 7,056,886
NPS PHARMACEUTICALS, INC.,)
Patent Owner.)
-----)

VIDEOTAPED DEPOSITION OF IVAN HOFMANN
Atlanta, Georgia
Friday, May 6, 2016
10:21 A.M.

HIGHLY CONFIDENTIAL

Job No: 107129
Reported by:
SUZANNE BEASLEY, RPR, CCR-B-1184

NPS Ex. 2170
CFAD v. NPS
IPR2015-00990

IVAN HOFMANN
INDEX TO EXAMINATION

Examination	Page No.
By Mr. Robinson	8
By Mr. Blake	270
By Mr. Robinson	292

INDEX TO EXHIBITS

Exhibit No.	Page No.
Exhibit 2161	17
List of drugs from Medicare.gov website Pharmaceutical Assistance Program (Medicare)	
Exhibit 2162	24
List of all drugs approved by the FDA	
Exhibit 2163	28
List of orphan drugs approved in the United States from 1983 to 2016	
Exhibit 2164	30
Medicare formulary	
Exhibit 2165	31
List of drugs with coupons or rebates from the website www.rxpharmacycoupons.com	
Exhibit 2166	33
Hofmann declaration and accompanying exhibits, consisting of 4 volumes	

1	IVAN HOFMANN	
2	Exhibit 2167	104
3	Article entitled "Complications of Parenteral Nutrition" in Gastroenterology Clinics of North America by Ukleja	
4		
5	Exhibit 2168	111
6	Printout from rebates.com	
7	Exhibit 2169	124
8	Review Article, "The Management of Long-Term Parenteral Nutrition," by Dibb and others	
9		
10	Exhibit 2170	133
11	Excerpt from the Merck Manual, Fifteenth Edition	
12		
13	Exhibit 2171	137
14	Wikipedia article on Refeeding Syndrome	
15	Exhibit 2172	159
16	Petition for Inter Partes Review of U.S. Patent No. 7,056,886 (Claims 46-52 and 61-75)	
17		
18	Exhibit 2173	171
19	Article called "AP Impact: Big Pharma Cashes in on HGH abuse"	
20		
21	Exhibit 2174	189
22	Memorandum opinion from Intendis GmbH, et al. versus Glenmark Pharmaceuticals Ltd., et al.	
23		
24	Exhibit 2175	192
25	Article entitled "Treatment Options for Acne Rosacea"	
26		
27	Exhibit 2176	201
28	Drugs.com, printout, "Pharmaceutical Sales 2010, Top 200 Drugs for 2010 by Sales"	
29		
30	Exhibit 2177	201
31	Actos label	

1	IVAN HOFMANN	
2	Exhibit 2178	201
3	Drugs.com printout, "Pharmaceutical Sales 2010, Top 200 Drugs for 2010 by Units Sold"	
4		
5	Exhibit 2179	203
6	National Diabetes Fact Sheet, 2011	
7	Exhibit 2180	206
8	Januvia label	
9		
10	Exhibit 2181	208
11	Lexapro label	
12	Exhibit 2182	209
13	NIH mental health website printout Entitled "Major Depression Among Adults	
14	Exhibit 2183	210
15	National Institute of Mental Health website, Major Depression Among Adolescents	
16		
17	Exhibit 2184	211
18	Anxiety and Depression Association of America website printout on GAD	
19		
20	Exhibit 2185	213
21	Novolog label	
22	Exhibit 2186	215
23	Orphan Drug Report 2014	
24		
25	Exhibit 2187	216
26	Advate label	
27	Exhibit 2188	217
28	Fast Facts sheet from hemophilia.org	
29		
30	Exhibit 2189	220
31	Revlimid label	
32	Exhibit 2190	221
33	National Cancer Institute Surveillance, Epidemiology and End Results Program SEER Stat Fact Sheet: Myeloma	
34		
35		

1	IVAN HOFMANN	
2	Exhibit 2191	222
3	Article from the American Journal of Medicine entitled "Epidemiology of Myelodysplastic Syndromes	
4		
5	Exhibit 2192	223
6	Article from Clinical Cancer Research entitled "Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies"	
7		
8	Exhibit 2193	225
9	Article entitled "Racial Differences in Mantle Cell Lymphoma in the United States"	
10		
11	Exhibit 2194	227
12	Velcade label	
13	Exhibit 2195	240
14	McKinsey report entitled Insights into Pharmaceuticals and Medical Products	
15	Exhibit 2196	242
16	Graph of NPS's stock price from 1/1/13 5/1/13	
17	Exhibit 2197	247
18	Hofmann's Original Graph, Monthly Adjusted Close Stock Price	
19	Exhibit 2198	251
20	Hofmann's Graph with Correction, Index of Monthly Adjusted Close Stock Price (Normalizing all prices to 1.0 in October 2012)	
21	Exhibit 2199	254
22	Hofmann's Graph with Correction, Extended Back to 2007, Index of Monthly Adjusted Close Stock Price (Taken back to 2007 and normalizing all prices to 1.0 in January 2007)	
23		
24		
25		

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.